Prescription medication · Orexin Receptor Antagonist
lemborexant
Also sold as Dayvigo. Dayvigo is used to treat insomnia in adults.
Data updated 2026-05-15
- 2,425
- FDA reportsLightly reported
- 11
- InteractionsSeveral interactions
- $10.79
- Brand price (NADAC)
What the data shows
lemborexant (Dayvigo) is a prescription Orexin Receptor Antagonist, among the least-reported drugs the FDA tracks (2,425 FDA reports), with 11 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
lemborexant (Dayvigo) is a prescription Orexin Receptor Antagonist. Dayvigo is used to treat insomnia in adults.
Dayvigo is a medicine that can help you fall asleep and stay asleep. It is for adults who have trouble with insomnia.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$10.79/unit
Generic Available
No
EISAI INC
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Dayvigo is used to treat insomnia in adults.
Common side effects
Feeling sleepy
Key warnings
Dayvigo can make you feel very sleepy, even the next day.
The sections below are summarized in plain English from lemborexant's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Dayvigo works by blocking orexin, a chemical in your brain that keeps you awake. By blocking orexin, Dayvigo helps you feel sleepy. This allows you to fall asleep and stay asleep.
Side Effects (from patient reports)
Based on 2,425 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for lemborexant, by number of reports
- Suicide Attempt
Suicide Attempt
133 reports
- Somnolence
Somnolence
128 reports
- Condition Aggravated
Condition Aggravated
117 reports
- Suicidal Ideation
Suicidal Ideation
115 reports
- Fall
Fall
94 reports
- Headache
Headache
84 reports
- Sleep Paralysis
Sleep Paralysis
82 reports
- Nausea
Nausea
80 reports
- Dizziness
Dizziness
76 reports
- Insomnia
Insomnia
75 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for lemborexant each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where lemborexant sits
lemborexant has more FDA adverse-event reports than 15% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is lemborexant; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 2,425 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2015–2025.
Total Reports
2,425
Reports Mentioning Death
267
11.0% of reports — not proof of cause
Hospitalization Reports
1,064
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 3 | SUICIDE ATTEMPT | 133 |
| 4 | SOMNOLENCE | 128 |
| 5 | CONDITION AGGRAVATED | 117 |
| 6 | SUICIDAL IDEATION | 115 |
| 7 | FALL | 94 |
| 8 | HEADACHE | 84 |
| 9 | SLEEP PARALYSIS | 82 |
| 10 | NAUSEA | 80 |
| 11 | DIZZINESS | 76 |
| 12 | INSOMNIA | 75 |
| 13 | NIGHTMARE | 74 |
| 14 | PYREXIA | 68 |
| 15 | MALAISE | 66 |
| 16 | HEPATIC FUNCTION ABNORMAL | 64 |
| 17 | ADVERSE DRUG REACTION | 62 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Dayvigo can make you feel very sleepy, even the next day. Be careful driving or doing other things that need you to be alert. Some people have sleep paralysis, hallucinations, or do things like sleepwalking while taking Dayvigo. Dayvigo may also worsen depression or suicidal thoughts. Do not drink alcohol while taking Dayvigo.
Known Drug Interactions
Lemborexant: Concomitant administration of fluconazole increased lemborexant C max and AUC by approximately 1.6- and 4.2-fold, respectively which is expected to increase risk of adverse reactions, such as somnolence. Avoid concomitant use of fluconazole with lemborexant.
Mechanism: Fluconazole causes a large increase in the amount of lemborexant in your body, which can make you feel dangerously sleepy.
Lemborexant (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Avoid concomitant use of VFEND with lemborexant.
Mechanism: Voriconazole prevents the body from processing lemborexant correctly, which can cause the sleep medication to build up to unsafe levels.
Examples: Bupropion, methadone
Mechanism: Lemborexant can speed up the process of clearing bupropion from your system, potentially making it less effective.
Examples: Strong CYP3A inhibitors: itraconazole, clarithromycin Moderate CYP3A inhibitors: fluconazole, verapamil Weak CYP3A inhibitors: chlorzoxazone, ranitidine Strong and Moderate CYP3A Inducers Clinical Impact: Concomitant use with a strong or moderate CYP3A inducer decreases lemborexant exposure, which may reduce DAYVIGO efficacy [see Clinical Pharmacology ( 12.3 )].
Mechanism: Verapamil slows down how your body gets rid of lemborexant, which can cause the sleep medicine to build up in your system.
Examples: Strong CYP3A inducers: rifampin, carbamazepine, St.
Mechanism: Carbamazepine causes your body to process lemborexant much faster, which makes the sleep medicine less effective.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
Can I drive after taking Dayvigo?
Can I drink alcohol with Dayvigo?
What should I do if I have strange experiences while taking Dayvigo?
Can Dayvigo make my depression worse?
What if Dayvigo stops working after a few weeks?
Can I take other sleep medicines with Dayvigo?
What if I have liver problems?
What if I am taking other medications?
How long does Dayvigo stay in my system?
What do the Dayvigo tablets look like?
What are the common side effects of lemborexant?
Does lemborexant interact with other medications?
What drug class is lemborexant?
What pregnancy or breastfeeding source fields are listed for lemborexant?
Related Medications in Orexin Receptor Antagonist
Other drugs grouped near lemborexant - same-class peers and common alternatives.
eszopiclone
Lunesta
Eszopiclone (Lunesta) is a medicine that helps you fall asleep and stay asleep.
Compare with lemborexant →
melatonin
Melatonin
Melatonin is a hormone supplement that can help with sleep.
Compare with lemborexant →
ramelteon
Rozerem
Ramelteon (Rozerem) is a prescription medicine that can help you fall asleep faster.
Compare with lemborexant →
suvorexant
Belsomra
Belsomra is a prescription medicine used to treat insomnia.
Compare with lemborexant →
tasimelteon
Hetlioz
Tasimelteon (Hetlioz) is a medicine that helps people with Non-24-Hour Sleep-Wake Disorder (Non-24) sleep better.
Compare with lemborexant →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for lemborexant: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 2,425.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 11.01%.
- desvenlafaxine Δ 0.01 pts · 3,267 reports · Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) 11.02%death share
- perphenazine Δ 0.03 pts · 2,013 reports · Typical Antipsychotic (Phenothiazine) 10.98%death share
- ticagrelor Δ 0.06 pts · 30,895 reports · P2Y12 Inhibitor (Antiplatelet) 10.95%death share
- tamsulosin Δ 0.08 pts · 18,628 reports · Alpha-1 Adrenergic Blocker 11.09%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on lemborexant
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for lemborexant
The FDA label for lemborexant (sold under brand names such as Dayvigo) classifies it as a prescription-only medication in the Orexin Receptor Antagonist class. Dayvigo is used to treat insomnia in adults. Official labeling lists 1 commonly reported side effect, including Feeling sleepy.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 2,425 voluntary reports. The database also lists 11 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: February 24, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages